{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:11:37Z","timestamp":1790734297235,"version":"4.1.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Becton, Dickinson & Company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Management of pneumococcal disease is complicated by high rates of antimicrobial resistance (AMR). This study assessed AMR trends for Streptococcus pneumoniae isolates from adults with pneumococcal disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From January 2011 to February 2020, we evaluated 30-day nonduplicate S. pneumoniae isolates from 290 US hospitals (BD Insights Research Database) from adults (\u226518 years) in inpatient and outpatient settings. Isolates were required to have \u22651 AMR result for invasive (blood, cerebrospinal fluid\/neurologic) or noninvasive (respiratory or ear\/nose\/throat) pneumococcal disease samples. Determination of AMR was based on facility reports of intermediate or resistant. Descriptive statistics and generalized estimated equations were used to assess variations over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Over the study period, 34\u2009039 S. pneumoniae isolates were analyzed (20\u2009749 [61%] from noninvasive sources and 13\u2009290 [39%] from invasive sources). Almost half (46.6%) of the isolates were resistant to \u22651 drug, and noninvasive isolates had higher rates of AMR than invasive isolates. Total S. pneumoniae isolates had high rates of resistance to macrolides (37.7%), penicillin (22.1%), and tetracyclines (16.1%). Multivariate modeling identified a significant increasing trend in resistance to macrolides (+1.8%\/year; P\u2009&amp;lt;\u2009.001). Significant decreasing trends were observed for penicillin (\u22121.6%\/year; P\u2009&amp;lt;\u2009.001), extended-spectrum cephalosporins (ESCs; \u22120.35%\/year; P\u2009&amp;lt;\u2009.001), and \u22653 drugs (\u22120.5%\/year; P\u2009&amp;lt;\u2009.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite decreasing trends for penicillin, ESCs, and resistance to \u22653 drugs, AMR rates are persistently high in S. pneumoniae isolates among US adults. Increasing macrolide resistance suggests that efforts to address AMR in S. pneumoniae may require antimicrobial stewardship efforts and higher-valent pneumococcal conjugate vaccines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac420","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T07:28:37Z","timestamp":1662103717000},"source":"Crossref","is-referenced-by-count":32,"title":["A Multicenter Evaluation of Trends in Antimicrobial Resistance Among <i>Streptococcus pneumoniae<\/i> Isolates From Adults in the United States"],"prefix":"10.1093","volume":"9","author":[{"given":"Salini","family":"Mohanty","sequence":"first","affiliation":[{"name":"Center for Observational and Real World Evidence (CORE), Merck & Co., Inc. , Rahway, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly D","family":"Johnson","sequence":"additional","affiliation":[{"name":"Center for Observational and Real World Evidence (CORE), Merck & Co., Inc. , Rahway, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-2012","authenticated-orcid":false,"given":"Kalvin C","family":"Yu","sequence":"additional","affiliation":[{"name":"Becton, Dickinson & Company , Franklin Lakes, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A","family":"Watts","sequence":"additional","affiliation":[{"name":"Becton, Dickinson & Company , Franklin Lakes, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5291-5446","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Becton, Dickinson & Company , Franklin Lakes, New Jersey , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"2022092607575039500_ofac420-B1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/adc.2010.191718","article-title":"Invasive pneumococcal disease","volume":"96","author":"Randle","year":"2011","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"2022092607575039500_ofac420-B2","article-title":"Antibiotic resistance threats in the United States","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2022092607575039500_ofac420-B3","article-title":"Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network","volume-title":"Streptococcus pneumoniae","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"2022092607575039500_ofac420-B4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2022092607575039500_ofac420-B5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2047-2994-3-16","article-title":"Attributable healthcare utilization and cost of pneumonia due to drug-resistant Streptococcus pneumoniae: a cost analysis","volume":"3","author":"Reynolds","year":"2014","journal-title":"Antimicrob Resist Infect Control"},{"key":"2022092607575039500_ofac420-B6","doi-asserted-by":"publisher","first-page":"ofab063","DOI":"10.1093\/ofid\/ofab063","article-title":"A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the United States","volume":"8","author":"Gupta","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022092607575039500_ofac420-B7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jinf.2020.07.035","article-title":"Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009\u20122017","volume":"81","author":"Suaya","year":"2020","journal-title":"J Infect"},{"key":"2022092607575039500_ofac420-B8","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa051642","article-title":"Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae","volume":"354","author":"Kyaw","year":"2006","journal-title":"N Engl J Med"},{"key":"2022092607575039500_ofac420-B9","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/infdis\/jir755","article-title":"Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines","volume":"205","author":"Hampton","year":"2012","journal-title":"J Infect Dis"},{"key":"2022092607575039500_ofac420-B10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/cid\/ciw067","article-title":"Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine","volume":"62","author":"Tomczyk","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2022092607575039500_ofac420-B11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7774\/cevr.2021.10.2.81","article-title":"Impact of vaccination on carriage of and infection by antibiotic-resistant bacteria: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2021","journal-title":"Clin Exp Vaccin Res"},{"key":"2022092607575039500_ofac420-B12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijid.2019.10.005","article-title":"Impact of vaccines on antimicrobial resistance","volume":"90","author":"Buchy","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2022092607575039500_ofac420-B13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1513\/AnnalsATS.201511-778FR","article-title":"Pneumococcal vaccination strategies. An update and perspective","volume":"13","author":"Berical","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2022092607575039500_ofac420-B14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022092607575039500_ofac420-B15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/14760584.2021.1880328","article-title":"Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence","volume":"20","author":"Niederman","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"2022092607575039500_ofac420-B16","doi-asserted-by":"crossref","first-page":"e2211111","DOI":"10.1001\/jamanetworkopen.2022.1111","article-title":"Incidence and estimated vaccine effectiveness against hospitalizations for all-cause pneumonia among older US adults who were vaccinated and not vaccinated with 13-valent pneumococcal conjugate vaccine","volume":"5","author":"Hsiao","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2022092607575039500_ofac420-B17","article-title":"Vaxneuvance","author":"US Food and Drug Administration","year":"2021"},{"key":"2022092607575039500_ofac420-B18","article-title":"Prevnar 20","author":"US Food and Drug Administration","year":"2021"},{"key":"2022092607575039500_ofac420-B19","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.1073\/pnas.1717161115","article-title":"Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR","volume":"115","author":"Sevilla","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022092607575039500_ofac420-B20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/infdis\/jiac154","article-title":"Impact of pneumococcal conjugate vaccines on antibiotic-nonsusceptible invasive pneumococcal disease in the United States","volume":"226","author":"Bajema","year":"2022","journal-title":"J Infect Dis"},{"key":"2022092607575039500_ofac420-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","article-title":"Surveillance of vaccination coverage among adult populations\u2014United States, 2018","volume":"70","author":"Lu","year":"2021","journal-title":"MMWR Surveill Summ"},{"key":"2022092607575039500_ofac420-B22","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMRW Morb Mortal Wkly Rep"},{"key":"2022092607575039500_ofac420-B23","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jamainternmed.2016.5651","article-title":"Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012","volume":"176","author":"Baggs","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2022092607575039500_ofac420-B24","first-page":"370","article-title":"Changes in US outpatient prescriptions from 2011\u20132016","volume":"70","author":"King","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022092607575039500_ofac420-B25","doi-asserted-by":"crossref","first-page":"e212007","DOI":"10.1001\/jamanetworkopen.2021.2007","article-title":"Assessment of the appropriateness of antimicrobial use in US hospitals","volume":"4","author":"Magill","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022092607575039500_ofac420-B26","doi-asserted-by":"publisher","first-page":"ofac039","DOI":"10.1093\/ofid\/ofac039","article-title":"Antibiotic resistance patterns and association with influenza season in the United States: a multicenter evaluation reveals surprising associations between influenza season and resistance in gram-negative pathogens","volume":"9","author":"Gupta","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2022092607575039500_ofac420-B27","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2021.07.502","article-title":"Evaluation of the in vitro activity of ceftaroline and comparators against Streptococcus pneumoniae isolates from the United States: results from 10 years of the AWARE surveillance program (2011\u20132020)","author":"Sader","year":"2021"},{"key":"2022092607575039500_ofac420-B28","doi-asserted-by":"crossref","first-page":"iv39","DOI":"10.1093\/jac\/dkz286","article-title":"Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007\u201316","volume":"74","author":"Golden","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2022092607575039500_ofac420-B29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1309\/502AUPR8VE67MBDE","article-title":"A laboratory-based, hospital-wide, electronic marker for nosocomial infection: the future of infection control surveillance?","volume":"125","author":"Brossette","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"2022092607575039500_ofac420-B30","article-title":"Census regions and divisions of the United States","author":"US Department of Commerce Economics and Statistics Administration, US Census Bureau"},{"key":"2022092607575039500_ofac420-B31","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1128\/AAC.00185-16","article-title":"Results from the Solithromycin International Surveillance Program (2014)","volume":"60","author":"Farrell","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022092607575039500_ofac420-B32","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1016\/j.vaccine.2019.09.065","article-title":"Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: emergence of drug-resistant non-vaccine serotypes","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"},{"key":"2022092607575039500_ofac420-B33","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2022092607575039500_ofac420-B34","doi-asserted-by":"publisher","first-page":"ofab062","DOI":"10.1093\/ofid\/ofab062","article-title":"Macrolides as empiric therapy for outpatients with pneumonia","volume":"8","author":"Musher","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022092607575039500_ofac420-B35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00019053-200725080-00005","article-title":"Direct costs in patients hospitalised with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US","volume":"25","author":"Paladino","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"2022092607575039500_ofac420-B36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3343\/alm.2019.39.6.537","article-title":"Serotype distribution and antimicrobial resistance of invasive and noninvasive Streptococcus pneumoniae isolates in Korea between 2014 and 2016","volume":"39","author":"Park","year":"2019","journal-title":"Ann Lab Med"},{"key":"2022092607575039500_ofac420-B37","article-title":"Pneumococcal disease: surveillance and reporting","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2022092607575039500_ofac420-B38","doi-asserted-by":"crossref","first-page":"101271","DOI":"10.1016\/j.eclinm.2022.101271","article-title":"Non-invasive pneumococcal pneumonia due to vaccine serotypes: a systematic review and meta-analysis","volume":"44","author":"Lansbury","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2022092607575039500_ofac420-B39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10935-015-0394-3","article-title":"Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013","volume":"36","author":"McLaughlin","year":"2015","journal-title":"J Prim Prev"},{"key":"2022092607575039500_ofac420-B40","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"2022092607575039500_ofac420-B41","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1128\/CVI.00381-13","article-title":"Invasive and noninvasive Streptococcus pneumoniae capsule and surface protein diversity following the use of a conjugate vaccine","volume":"20","author":"Croney","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"2022092607575039500_ofac420-B42","doi-asserted-by":"crossref","first-page":"512.e1","DOI":"10.1016\/j.cmi.2019.09.008","article-title":"Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017","volume":"26","author":"Varghese","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2022092607575039500_ofac420-B43","first-page":"987\u201399","article-title":"Estimates of the health and economic burden of pneumococcal infections attributable to the 15-valent pneumococcal conjugate vaccine serotypes in the USA","volume":"11","author":"Owusu-Edusei","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2022092607575039500_ofac420-B44","first-page":"4700\u20138","article-title":"Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States","volume":"40","author":"Huang","year":"2022","journal-title":"Huang Vaccine"},{"key":"2022092607575039500_ofac420-B45","article-title":"Healthy People 2020. Immunization and infectious diseases","author":"Office of Disease Prevention and Health Promotion","year":"2022"},{"key":"2022092607575039500_ofac420-B46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/003335491613100105","article-title":"A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria: recommendations from the National Vaccine Advisory Committee","volume":"131","author":"National Vaccine Advisory Committee","year":"2016","journal-title":"Public Health Rep"},{"key":"2022092607575039500_ofac420-B47","article-title":"Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance. An Action Framework and annexe to Immunization Agenda 2030","author":"World Health Organization","year":"2021"},{"key":"2022092607575039500_ofac420-B48","doi-asserted-by":"crossref","first-page":"12896","DOI":"10.1073\/pnas.1721095115","article-title":"Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects","volume":"115","author":"Klugman","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022092607575039500_ofac420-B49","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1073\/pnas.1718712115","article-title":"Vaccination can drive an increase in frequencies of antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae","volume":"115","author":"Obolski","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022092607575039500_ofac420-B50","doi-asserted-by":"crossref","first-page":"e20172034","DOI":"10.1542\/peds.2017-2034","article-title":"Playing \u201cwhack-a-mole\u201d with pneumococcal serotype eradication","volume":"40","author":"Swanson","year":"2017","journal-title":"Pediatrics"},{"key":"2022092607575039500_ofac420-B51","article-title":"Core elements of antibiotic stewardship","author":"Centers for Disease Control and Prevention","year":"2021"},{"key":"2022092607575039500_ofac420-B52","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing. CLSI Document M100","author":"Clinical and Laboratory Standards Institute (CLSI).","year":"2021","edition":"31st ed"},{"key":"2022092607575039500_ofac420-B53","doi-asserted-by":"crossref","first-page":"e00203","DOI":"10.1128\/JCM.00203-19","article-title":"Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories","volume":"57","author":"Humphries","year":"2019","journal-title":"J Clin Microbiol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac420\/45662321\/ofac420.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/9\/ofac420\/46041768\/ofac420.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/9\/ofac420\/46041768\/ofac420.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T07:58:50Z","timestamp":1664179130000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac420\/6686537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac420","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,9,1]]},"article-number":"ofac420"}}